Ep158: Iron infusions and fracture risk. A safety signal for ferric carboxymaltose

One in twenty Australian women of reproductive age are treated with intravenous iron supplementation, almost exclusively with ferric carboxymaltose. Usually sold under the name Ferinject or also Ferricarbo and Ferivo, this formulation is well-known to reduce serum phosphate in 50 to 70% of patients taking it, recently published findings reveal that it is associated with a significant increase in fracture risk and osteomalacia. Cohort studies presented in July in the journal Blood show...